Phase II randomized trial on dose-escalated sorafenib (S) versus best supportive care (BSC) in patients with advanced hepatocellular carcinoma (HCC) with disease progression on prior S treatment.
暂无分享，去创建一个
R. Labianca | C. Porta | C. Boni | R. Ceriani | G. Torzilli | A. Ardizzoni | L. Rimassa | L. Giordano | T. Pressiani | E. Cortesi | C. Carnaghi | A. Santoro | F. Artioli | S. Fagiuoli | M. Tommasini | G. Covini | R. Lutman | L. Latini | P. Foa | G. Torzilli | C. Porta | R. Ceriani | N. Locopo | C Carnaghi | G Covini